Testing CT1192 cells for lupus that hasn't responded to treatment
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new treatment called CT1192, which uses your own immune cells (T-cells) that are modified to target and calm overactive immune cells causing lupus. It is designed for people with moderate to severe lupus that hasn't improved with standard therapies like steroids, immunosuppressants, or biologics.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with lupus (SLE) for at least 6 months and your disease is still active despite treatment.
- Your lupus activity score (SLEDAI-2K) is 7 or more, or you have serious organ problems like kidney inflammation (nephritis) or low platelet count.
- You are between 18 and 60 years old.
- You have not had certain B-cell targeting drugs (like rituximab) in the last 6 months, or other biologics (like belimumab) in the last 12 weeks.
- You are not pregnant, and you agree to use effective birth control for at least 1 year after treatment.
- You have adequate organ function, such as acceptable kidney function (creatinine clearance ≥ 50 mL/min), liver and blood counts within safe limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new CAR-T cell treatment (called CT1195E) can help people with lupus that hasn't improved with standard medicines. CAR-T cells are specially trained immune cells that seek out and destroy certain faulty immune cells, which may reduce lupus symptoms. The trial is for people with moderate to severe active lupus affecting organs like the kidneys, heart, or blood system.
This trial tests whether a type of immune cell therapy called CAR-T can help people with active lupus that hasn't responded well to standard treatments. It aims to reduce disease activity and improve symptoms.
This trial tests a new cell therapy (CT1190B) for people with moderate to severe lupus or systemic sclerosis that has not responded to standard treatments. The therapy aims to calm the overactive immune system causing these autoimmune diseases.
This trial tests a new CAR-T cell therapy for people with severe lupus that hasn't improved with standard treatments. The therapy uses specially designed immune cells to target and destroy cells causing the disease.
This trial tests a new type of cell therapy called CAR-T cells that target a protein called CD70 on immune cells. The goal is to see if it can help people with active lupus that has not improved with standard treatments.
This trial tests a new immune cell therapy (CAR NK cells) for people with moderate to severe lupus that hasn't responded well to standard treatments. The therapy targets a protein called CD19 on certain immune cells to calm the overactive immune system.
Hear when a new Systemic Lupus Erythematosus (SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.